12 Best High Short Interest Stocks With Highest Upside Potential
On May 29, Melissa Brown, Managing Director of Investment Decision Research, joined BNN Bloomberg to assess the health of the US economy.
Spyre Therapeutics Inc. (SYRE)
Market is closed
Sector: Pharmaceutical Preparations
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Perceptive Advisors Joseph Edelman | 3,783,225 | $190,825,869 | +24% | 3.73% |
| 2. | Driehaus Capital Richard Driehaus | 2,790,785 | $140,767,195 | -4% | 1.03% |
| 3. | Paradigm Biocapital Advisors Senai Asefaw | 1,957,266 | $98,724,497 | +34% | 2.02% |
| 4. | Commodore Capital Egen Atkinson And Michael Kramarz | 1,912,380 | $96,460,447 | -20% | 5.58% |
| 5. | Tang Capital Management Kevin C. Tang | 1,892,200 | $95,442,568 | 4.85% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $0.56 | 90,000 | $50,472.00 | 90,000 | 2022-08-25 | Filing | |
| $0.71 | 28,200 | $20,022.00 | 36,200 | 2022-06-08 | Filing | |
| $2.34 | 80,079 | $187,705.18 | 550,540 | 2022-03-16 | Filing | |
| $1.86 | 42,417 | $78,942.28 | 473,461 | 2022-03-15 | Filing | |
| $1.93 | 67,472 | $130,220.96 | 431,044 | 2022-03-14 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $75.35 | 19,269 | $1,451,919.15 | 88,606 | 2026-05-08 | Filing | |
| $74.76 | 24,814 | $1,855,094.64 | 107,875 | 2026-05-08 | Filing | |
| $73.72 | 33,513 | $2,470,578.36 | 132,689 | 2026-05-08 | Filing | |
| $72.57 | 2,404 | $174,458.28 | 166,202 | 2026-05-08 | Filing | |
| $71.37 | 12,500 | $892,125.00 | 97,994 | 2026-05-01 | Filing |
Institutional Investors' Holdings
Filing Period:
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 11,781,024 | $594,234,851 | 0.03% | |
| 2. | 5,521,221 | $278,490,385 | 0% | |
| 3. | 4,171,996 | $210,435,478 | 2.09% | |
| 4. | 4,018,101 | $202,673,014 | 14.64% | |
| 5. | 3,685,448 | $185,893,997 | 6.94% |
News See All
10 Small-Cap Stocks That Are On Fire Right Now
On April 22, Bipan Rai, Head of ETF strategy at BMO Global Asset Management, joined BNN Bloomberg to discuss the transition of the global economy into a stagflation-like regime in Q2 2026.
Billionaire Joe Edelman's 10 Stock Picks with Huge Upside Potential
Joseph Edelman, the billionaire chief of New York-based Perceptive Advisors, specializes in the biotechnology and life sciences sectors.
10 Best 52-Week High US Stocks to Buy
“Investors appear to be treating an end to the US-Israeli war with Iran as a foregone conclusion, as the S&P 500 closes above 7,000.” This is the deck on the New York Times’ report on the S&P 500...
10 Stocks With Monster Returns
Notably, investors poured funds into industries with promising growth prospects, namely semiconductor and quantum computing, while some favored pharmaceutical players thanks to progress on their pipeline...
10 Stocks With Eye-Popping Gains
Nasdaq announced late Friday that Sandisk Corp. (NASDAQ:SNDK) is set to replace Atlassian Corp.
Spyre Therapeutics (SYRE) Set POC Readout Priorities for 2026
As of the close of play on February 12, consensus sentiment around Spyre Therapeutics (NASDAQ:SYRE) was strongly bullish.
17 Biotechnology Stocks with More Than 50% Upside
2025 was a year characterized by both challenges and opportunities for the biotechnology sector.
Wall Street Bullish on Spyre Therapeutics, Inc. (SYRE) with Strong Buy Rating
The update follows Mizuho’s initiation of coverage on the stock on December 18 with an Outperform rating and a share price target of $53, where it cited potential in the company’s pipeline of anti...
14 Best Booming Stocks to Buy Right Now
In a report released on January 9, Goldman Sachs said that it expects the index to rally 12% in 2026.
Hedge Fund Resource Center